Literature DB >> 28493230

[Methodology report of the 2017 guidelines on fibromyalgia syndrome].

W Häuser1,2, M Nothacker3.   

Abstract

BACKGROUND: The regular update of the guidelines on fibromyalgia syndrome, AWMF number 145/004, was planned for April 2017.
METHODS: The guidelines were developed by 13 scientific societies and 2 patient self-help organizations coordinated by the German Pain Society. Working groups (n = 8) with a total of 42 members were formed balanced with respect to gender, medical expertise, position in the medical or scientific hierarchy and potential conflicts of interest.
RESULTS: A systematic search of the literature from December 2010 to May 2016 was performed in the Cochrane library, MEDLINE, PsycINFO and Scopus databases. Levels of evidence were assigned according to the classification system of the Oxford Centre for Evidence-Based Medicine version 2009. The strength of recommendations was achieved by multiple step formalized procedures to reach a consensus. Efficacy, risks, patient preferences and applicability of therapies available were weighed up against each other. The guidelines were reviewed and approved by the board of directors of the societies engaged in the development of the guidelines.
CONCLUSION: The guidelines are published in several forms, i.e. complete and short scientific versions and clinical practice and patient versions.

Entities:  

Keywords:  Association of the Scientific Medical Societies in Germany; Fibromyalgia syndrome; German Pain Society; Guidelines; Methodology

Mesh:

Year:  2017        PMID: 28493230     DOI: 10.1007/s00482-017-0209-y

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  10 in total

1.  [Methodological basis for the development of consensus recommendations].

Authors:  J C Hoffmann; I Fischer; W Höhne; M Zeitz; H-K Selbmann
Journal:  Z Gastroenterol       Date:  2004-09       Impact factor: 2.000

2.  [Methodological fundamentals of the development of the guideline].

Authors:  W Häuser; K Bernardy; H Wang; I Kopp
Journal:  Schmerz       Date:  2012-06       Impact factor: 1.107

3.  [Treatment and healthcare costs of fibromyalgia syndrome in Germany: analysis of the data of the Barmer health insurance (BEK) from 2008-2009].

Authors:  U Marschall; B Arnold; W Häuser
Journal:  Schmerz       Date:  2011-08       Impact factor: 1.107

4.  [Guidelines for the diagnosis and treatment of the fibromyalgia syndrome].

Authors:  Jacob N Ablin; Howard Amital; Michael Ehrenfeld; Valerie Aloush; Ori Elkayam; Pnina Langevitz; Dror Mevorach; Reuven Mader; Tali Sachar; Daniela Amital; Dan Buskila
Journal:  Harefuah       Date:  2013-12

5.  2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary.

Authors:  Mary-Ann Fitzcharles; Peter A Ste-Marie; Don L Goldenberg; John X Pereira; Susan Abbey; Manon Choinière; Gordon Ko; Dwight E Moulin; Pantelis Panopalis; Johanne Proulx; Yoram Shir
Journal:  Pain Res Manag       Date:  2013 May-Jun       Impact factor: 3.037

Review 6.  [Methodology of the development of the updated LONTS guidelines for long-term administration of opioids in noncancer pain].

Authors:  W Häuser; P Klose; P Welsch; F Petzke; M Nothacker; I Kopp
Journal:  Schmerz       Date:  2015-02       Impact factor: 1.107

7.  [Methodological fundamentals for the development of the guideline].

Authors:  K Bernardy; P Klose; N Uçeyler; I Kopp; W Häuser
Journal:  Schmerz       Date:  2008-06       Impact factor: 1.107

Review 8.  Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.

Authors:  Andrea Cipriani; Toshiaki A Furukawa; Georgia Salanti; John R Geddes; Julian Pt Higgins; Rachel Churchill; Norio Watanabe; Atsuo Nakagawa; Ichiro M Omori; Hugh McGuire; Michele Tansella; Corrado Barbui
Journal:  Lancet       Date:  2009-02-28       Impact factor: 79.321

9.  [Development of national guidelines for depression].

Authors:  Martin Härter; C Klesse; I Bermejo; M Lelgemann; S Weinbrenner; G Ollenschläger; I Kopp; M Berger
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2008-04       Impact factor: 1.513

10.  Fibromyalgia syndrome module at OMERACT 9: domain construct.

Authors:  Philip Mease; Lesley M Arnold; Ernest H Choy; Daniel J Clauw; Leslie J Crofford; Jennifer M Glass; Susan A Martin; Jessica Morea; Lee Simon; C Vibeke Strand; David A Williams
Journal:  J Rheumatol       Date:  2009-10       Impact factor: 4.666

  10 in total
  11 in total

Review 1.  [Definition, classification, clinical diagnosis and prognosis of fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles].

Authors:  W Eich; K-J Bär; M Bernateck; M Burgmer; C Dexl; F Petzke; C Sommer; A Winkelmann; W Häuser
Journal:  Schmerz       Date:  2017-06       Impact factor: 1.107

Review 2.  [Physiotherapy, occupational therapy and physical therapy in fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles].

Authors:  A Winkelmann; H Bork; W Brückle; C Dexl; P Heldmann; P Henningsen; L Krumbein; V Pullwitt; M Schiltenwolf; W Häuser
Journal:  Schmerz       Date:  2017-06       Impact factor: 1.107

3.  [Twelve years of the S3 guideline Fibromyalgia Syndrome-a never-ending war?]

Authors:  W Häuser; E Kühn; B Wolf; M Nothacker; F Petzke
Journal:  Schmerz       Date:  2017-06       Impact factor: 1.107

Review 4.  [Psychotherapy and psychological procedures for fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles].

Authors:  V Köllner; K Bernardy; W Greiner; L Krumbein; H Lucius; M Offenbächer; M Sarholz; M Settan; W Häuser
Journal:  Schmerz       Date:  2017-06       Impact factor: 1.107

Review 5.  [General treatment principles, coordination of care and patient education in fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles].

Authors:  F Petzke; W Brückle; U Eidmann; P Heldmann; V Köllner; T Kühn; H Kühn-Becker; M Strunk-Richter; M Schiltenwolf; M Settan; M von Wachter; M Weigl; W Häuser
Journal:  Schmerz       Date:  2017-06       Impact factor: 1.107

Review 6.  [Complementary and alternative procedures for fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles].

Authors:  J Langhorst; P Heldmann; P Henningsen; K Kopke; L Krumbein; H Lucius; A Winkelmann; B Wolf; W Häuser
Journal:  Schmerz       Date:  2017-06       Impact factor: 1.107

7.  [A weakly negative recommendation is not an absolute "no" : Comment on AWMF guideline recommendations for cannabis-based medicines in fibromyalgia syndrome].

Authors:  W Häuser; F Petzke; M Nothacker
Journal:  Schmerz       Date:  2018-10       Impact factor: 1.107

Review 8.  [Multimodal therapy of fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles].

Authors:  M Schiltenwolf; U Eidmann; V Köllner; T Kühn; M Offenbächer; F Petzke; M Sarholz; M Weigl; B Wolf; W Häuser
Journal:  Schmerz       Date:  2017-06       Impact factor: 1.107

Review 9.  [Etiology and pathophysiology of fibromyalgia syndrome : Updated guidelines 2017, overview of systematic review articles and overview of studies on small fiber neuropathy in FMS subgroups].

Authors:  N Üçeyler; M Burgmer; E Friedel; W Greiner; F Petzke; M Sarholz; M Schiltenwolf; A Winkelmann; C Sommer; W Häuser
Journal:  Schmerz       Date:  2017-06       Impact factor: 1.107

Review 10.  [Drug therapy of fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles].

Authors:  C Sommer; R Alten; K-J Bär; M Bernateck; W Brückle; E Friedel; P Henningsen; F Petzke; T Tölle; N Üçeyler; A Winkelmann; W Häuser
Journal:  Schmerz       Date:  2017-06       Impact factor: 1.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.